OstEvo - Osteosarcoma Evolves

Summary

The researchers are doing this study to find out whether adding gefitinib, trametinib, disulfiram, and sunitinib to standard chemotherapy is a more effective treatment approach for people with osteosarcoma than standard chemotherapy on its own. The researchers will also look at the safety of adding these drugs to standard chemotherapy. The researchers will also use the additional research biopsies from Cohort 1 participants to learn more about how osteosarcoma survives during chemotherapy.

Eligibility

Age range

6–49 years

Sex

All

Healthy volunteers

No

Interventions

• Drug
  Methotrexate

  Methotrexate 12 g/m\^2 (max dose 20 grams) intravenously over 4 hours or as per institutional standard.

• Drug
  Doxorubicin

  Doxorubicin 37.5 mg/m\^2 intravenously over 15 to 30 minutes or as per institutional standard.

• Drug
  Cisplatin

  Cisplatin 60 mg/m\^2 intravenously over 4 hours or as per institutional standard.

• Drug
  Gefitinib

  Gefitinib 400 mg/m\^2/dose (maximum dose 250 mg) orally daily for 14 days (14 doses)

• Drug
  Trametinib

  Trametinib will be dispensed as per institutional standard.

• Drug
  Disulfiram

  Disulfiram 250 to 500 mg orally once daily for 14 days

• Drug

Locations (7)